What is Windlas Biotech Ltd (WINDLAS) share price today?

Windlas Biotech Ltd (WINDLAS) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/WINDLAS for the latest live price, technical analysis, and AI-powered insights.

How to analyse WINDLAS stock?

VestAI provides comprehensive WINDLAS stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Windlas Biotech Ltd in?

Windlas Biotech Ltd (WINDLAS) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Windlas Biotech Ltd

Name: Windlas Biotech Ltd (WINDLAS) Financial Metrics
Creator: VestAI

WINDLAS

NSE· Healthcare

₹844.25

-6.00 (-0.71%)

Updated 11:30 am IST

52W Low · ₹697.4052W High · ₹1,097.90

Mid Range

Market Cap

₹1680.10L Cr

Volume

49.0K

Prev Close

₹840.15

ISIN

INE0H5O01029

Orion Score

Fundamentals-based quality & risk · not a recommendation

71/100

Quality

Windlas Biotech Ltd scores 71/100 (Quality) on the Orion Score — moderate business quality (69), strong growth (78), strong balance-sheet safety (85) and fair valuation (48). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 1.3× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 4/9Altman Z Safe(6.73)Beneish M Clean(-2.39)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

52/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.06x — lean balance sheet

QUALITY

Average

ROCE 12.6% — decent returns

MOMENTUM

Neutral

RSI 54.4 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 26.11
ROCE: 12.62%
ROE (1Y): 12.23%
D/E Ratio: 0.06x
OPM: 7.25%
TTM EPS: ₹31.18
Dividend Yield: 71.00%
Qtrly Sales: ₹238.50 Cr
Qtrly Profit: ₹15.99 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹238.5	₹15.99	7.3%	₹7.49
Q3 2026	₹233.1	₹15	7.2%	₹7.05
Q2 2026	₹222.4	₹17.8	9.4%	₹8.40
Q1 2026	₹210.09	₹17.66	9.1%	₹8.34
Q4 2025	₹202.71	₹16.28	8.5%	₹7.69

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2026	₹904.09	₹66.46	₹122.55	8.2%
FY 2025	₹759.88	₹60.99	₹112.12	8.7%
FY 2024	₹628.88	₹58.19	₹91.64	10.3%
FY 2023	₹510.58	₹42.63	₹70.19	9.4%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
WINDLAS ★	₹1,680 Cr	26.11	12.62%	12.23%	0.06x	7.25%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹90,029 Cr	25.94	12.55%	9.93%	0.21x	15.11%
ABBOTINDIAAbbott India Limited	₹57,724 Cr	36.63	36.14%	34.46%	0.04x	27.01%
AJANTPHARMAjanta Pharma Limited	₹41,836 Cr	39.55	27.99%	25.39%	0.06x	51.40%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹760.45	₹626.21	₹528.98	₹491.01
Equity	₹505.77	₹449.94	₹402.27	₹394.78
Total Debt	₹32.6	₹3.64	₹4.99	₹6.64
Cash	₹0.42	₹5.29	₹3.69	₹0.57
Net Debt	₹26.69	—	—	₹5.55
Working Capital	₹275.69	₹259.54	₹232.29	₹287.67

Shareholding Pattern

Q3 FY2026

Promoter

61.98%

FII

0.93%

DII

11.44%

Public

25.64%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q3 FY2026	61.98%	0.93% ↓	11.44%	25.64% ↑
Q2 FY2026	61.98% ↓	1.11% ↓	11.44% ↑	25.48% ↑
Q1 FY2026	62.34%	1.44% ↓	11.22% ↑	25.01% ↓
Q4 FY2025	62.34% ↓	1.52% ↓	10.89% ↑	25.25% ↓
Q3 FY2025	62.51%	1.55% ↓	10.26% ↑	25.67% ↓
Q2 FY2025	62.51%	2% ↑	9.58% ↓	25.91% ↑
Q1 FY2025	62.51% ↓	1.59% ↑	10.35% ↓	25.55% ↑
Q4 FY2024	62.82%	1.18%	11.82%	24.19%

Corporate Actions

Ex-Date	Action	Details
2026-07-16	DIVIDEND	Dividend - Rs 6.30 Per Share
2026-04-24	BUYBACK	Buy Back

Funds Holding This Stock

5 mutual fund schemes

UTI Healthcare Fund Direct GrowthUTI

1.16%

₹15 Cr

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct GrowthICICI_PRUDENTIAL

0.96%

₹62 Cr

ICICI Prudential Smallcap Fund Direct Plan GrowthICICI_PRUDENTIAL

0.16%

₹14 Cr

Bandhan Small Cap Fund Direct GrowthIDFC

0.09%

₹24 Cr

Bandhan BSE Healthcare Index Fund Direct GrowthIDFC

0.04%

₹0 Cr

Analyse WINDLAS with Orion AI

Ask: "Is Windlas Biotech Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Windlas Biotech Ltd (WINDLAS) Stock

Windlas Biotech Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE0H5O01029. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.